367 related articles for article (PubMed ID: 27272266)
1. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Torres A; Mouton JW; Pea F
Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
[TBL] [Abstract][Full Text] [Related]
2. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Syed YY
Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
[TBL] [Abstract][Full Text] [Related]
3. Ceftobiprole: pharmacokinetics and PK/PD profile.
Azanza Perea JR; Sádaba Díaz de Rada B
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):11-16. PubMed ID: 31364336
[TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole for the treatment of pneumonia: a European perspective.
Liapikou A; Cillóniz C; Torres A
Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
6. Ceftobiprole for the treatment of pneumonia.
Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
Lagacé-Wiens PR; Rubinstein E
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Horn KS; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
Murthy B; Schmitt-Hoffmann A
Clin Pharmacokinet; 2008; 47(1):21-33. PubMed ID: 18076216
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K
Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489
[TBL] [Abstract][Full Text] [Related]
11. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
[TBL] [Abstract][Full Text] [Related]
12. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
13. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
Falcó V; Burgos J; Almirante B
Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
[TBL] [Abstract][Full Text] [Related]
14. Ceftobiprole: drug evaluation and place in therapy.
Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
[TBL] [Abstract][Full Text] [Related]
17. Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
Montravers P; Harpan A; Guivarch E
Adv Ther; 2016 Feb; 33(2):151-66. PubMed ID: 26861846
[TBL] [Abstract][Full Text] [Related]
18. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
19. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
20. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
